Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis

Bookmark and Share
Published: 19 Dec 2019
Views: 328
Rating:
Save
Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

Dr Jeffrey Lancet speaks to ecancer at the 2019 ASH meeting in Orlando about a phase 1 study looking at the outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3.

He explains that therapy-related AML is a difficult to treat type of secondary AML and is frequently associated with previous chemotherapy exposure.

Dr Lancet reports that for the therapy-related AML patients the overall survival was better with the CPX-351.